{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T19:30:35Z","timestamp":1792438235483,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bone.2026.117873","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T15:53:09Z","timestamp":1774885989000},"page":"117873","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The effects of anti-Parkinsonian medications on bone mineral density: A systematic review"],"prefix":"10.1016","volume":"208","author":[{"given":"M\u00edche\u00e1l","family":"\u00d3 Breasail","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motaz B.","family":"El-Leissy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan P.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Mesinovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Blacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saman","family":"Heshmat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Mahant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Girgis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Ebeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayse","family":"Zengin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2026.117873_bb0005","series-title":"Parkinson's Disease: Pathogenesis and Clinical Aspects","article-title":"Parkinson's Disease: Etiology, Neuropathology, and Pathogenesis","author":"Kouli","year":"2018"},{"key":"10.1016\/j.bone.2026.117873_bb0010","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-080952","article-title":"Projections for prevalence of Parkinson\u2019s disease and its driving factors in 195 countries and territories to 2050: modelling study of global burden of disease study 2021","volume":"388","author":"Su","year":"2025","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.bone.2026.117873_bb0015","article-title":"Clinical features of Parkinson\u2019s disease: the evolution of critical symptoms","volume":"9","author":"Varadi","year":"2020","journal-title":"Biol.-Basel"},{"issue":"2","key":"10.1016\/j.bone.2026.117873_bb0020","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1210\/endrev\/bnab028","article-title":"Secondary osteoporosis","volume":"43","author":"Ebeling","year":"2022","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bone.2026.117873_bb0025","article-title":"Bone health in Parkinson\u2019s disease: a comprehensive review of bone involvement and its pathophysiological mechanisms","volume":"12","author":"Toussirot","year":"2025","journal-title":"Front. Med. (Lausanne)"},{"issue":"3","key":"10.1016\/j.bone.2026.117873_bb0030","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/17446651.2020.1756772","article-title":"Parkinson\u2019s disease and osteoporosis: basic and clinical implications","volume":"15","author":"Figueroa","year":"2020","journal-title":"Expert. Rev. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.bone.2026.117873_bb0035","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00198-022-06562-0","article-title":"Fracture risk in Parkinson\u2019s disease according to its severity and duration","volume":"34","author":"Koo","year":"2023","journal-title":"Osteoporos. Int."},{"issue":"5","key":"10.1016\/j.bone.2026.117873_bb0040","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1159\/000513730","article-title":"Hip fracture in patients with Parkinson\u2019s disease and related mortality: a population-based study in Korea","volume":"67","author":"Nam","year":"2021","journal-title":"Gerontology"},{"issue":"6","key":"10.1016\/j.bone.2026.117873_bb0045","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.bone.2012.02.639","article-title":"Effect of co-morbidities on fracture risk: findings from the global longitudinal study of osteoporosis in women (GLOW)","volume":"50","author":"Dennison","year":"2012","journal-title":"Bone"},{"issue":"23","key":"10.1016\/j.bone.2026.117873_bb0050","doi-asserted-by":"crossref","first-page":"e2448","DOI":"10.1212\/WNL.0000000000009452","article-title":"Fractures in the prodromal period of Parkinson disease","volume":"94","author":"Camacho-Soto","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.bone.2026.117873_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2019.115173","article-title":"The risk of hip and non-vertebral fractures in patients with Parkinson\u2019s disease and parkinsonism: a systematic review and meta-analysis","volume":"132","author":"Schini","year":"2020","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.bone.2026.117873_bb0060","doi-asserted-by":"crossref","DOI":"10.2106\/JBJS.L.01317","article-title":"Relative mortality in U.S. Medicare beneficiaries with Parkinson disease and hip and pelvic fractures","volume":"96","author":"Harris-Hayes","year":"2014","journal-title":"J. Bone Joint Surg. Am."},{"issue":"11","key":"10.1016\/j.bone.2026.117873_bb0065","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s00402-015-2298-3","article-title":"Impact of Parkinson\u2019s disease on the acute care treatment and medium-term functional outcome in geriatric hip fracture patients","volume":"135","author":"Bliemel","year":"2015","journal-title":"Arch. Orthop. Trauma Surg."},{"issue":"7","key":"10.1016\/j.bone.2026.117873_bb0070","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1007\/s00167-018-4970-y","article-title":"Parkinson\u2019s disease increases the risk of perioperative complications after total knee arthroplasty: a nationwide database study","volume":"27","author":"Newman","year":"2019","journal-title":"Knee Surg. Sports Traumatol. Arthrosc."},{"issue":"6","key":"10.1016\/j.bone.2026.117873_bb0075","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.injury.2022.03.015","article-title":"Postoperative complications, mortality, and quality of in-hospital care among hip fracture patients with Parkinson's disease","volume":"53","author":"Nguyen","year":"2022","journal-title":"Injury"},{"issue":"3","key":"10.1016\/j.bone.2026.117873_bb0080","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/mdc3.14311","article-title":"Management of osteoporosis in Parkinson\u2019s disease: a systematic review of clinical practice guidelines","volume":"12","author":"M","year":"2025","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.bone.2026.117873_bb0085","article-title":"Parkinson\u2019s disease and the bones","volume":"141","author":"Gnadinger","year":"2011","journal-title":"Swiss Med. Wkly."},{"issue":"2","key":"10.1016\/j.bone.2026.117873_bb0090","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ncl.2019.12.002","article-title":"Pharmacologic treatment of motor symptoms associated with Parkinson disease","volume":"38","author":"Poewe","year":"2020","journal-title":"Neurol. Clin."},{"issue":"21 Suppl 4","key":"10.1016\/j.bone.2026.117873_bb0095","first-page":"S1","article-title":"The scientific and clinical basis for the treatment of Parkinson disease (2009)","volume":"72","author":"Olanow","year":"2009","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.bone.2026.117873_bb0100","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00702-023-02623-8","article-title":"Clinical benefit of MAO-B and COMT inhibition in Parkinson\u2019s disease: practical considerations","volume":"130","author":"Regensburger","year":"2023","journal-title":"J. Neural Transm. (Vienna)"},{"issue":"2","key":"10.1016\/j.bone.2026.117873_bb0105","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/ane.12106","article-title":"Elevated homocysteine levels in levodopa-treated idiopathic Parkinson\u2019s disease: a meta-analysis","volume":"128","author":"Hu","year":"2013","journal-title":"Acta Neurol. Scand."},{"issue":"1\u20132","key":"10.1016\/j.bone.2026.117873_bb0110","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.neulet.2006.05.040","article-title":"Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson\u2019s disease","volume":"404","author":"Religa","year":"2006","journal-title":"Neurosci. Lett."},{"issue":"7","key":"10.1016\/j.bone.2026.117873_bb0115","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1359\/jbmr.060406","article-title":"Homocysteine enhances bone resorption by stimulation of osteoclast formation and activity through increased intracellular ROS generation","volume":"21","author":"Koh","year":"2006","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"10.1016\/j.bone.2026.117873_bb0120","doi-asserted-by":"crossref","DOI":"10.1515\/cclm-2012-0605","article-title":"The role of homocysteine in bone remodeling","volume":"51","author":"Vacek","year":"2013","journal-title":"Clin. Chem. Lab. Med."},{"issue":"1","key":"10.1016\/j.bone.2026.117873_bb0125","doi-asserted-by":"crossref","first-page":"13768","DOI":"10.1038\/s41598-019-50336-4","article-title":"Bone loss caused by dopaminergic degeneration and levodopa treatment in Parkinson\u2019s disease model mice","volume":"9","author":"Handa","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bone.2026.117873_bb0130","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3233\/JPD-230168","article-title":"Addressing comorbidities in people with Parkinson\u2019s disease: considerations from an expert panel","volume":"14","author":"Carroll","year":"2024","journal-title":"J. Parkinsons Dis."},{"issue":"8","key":"10.1016\/j.bone.2026.117873_bb0135","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson\u2019s disease","volume":"33","author":"Fox","year":"2018","journal-title":"Mov. Disord."},{"issue":"9","key":"10.1016\/j.bone.2026.117873_bb0140","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.recesp.2021.06.016","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"74","author":"Page","year":"2021","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.bone.2026.117873_bb0145","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.bone.2026.117873_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.envint.2024.108602","article-title":"A tool to assess risk of bias in non-randomized follow-up studies of exposure effects (ROBINS-E)","volume":"186","author":"Higgins","year":"2024","journal-title":"Environ. Int."},{"issue":"1","key":"10.1016\/j.bone.2026.117873_bb0155","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res. Synth. Methods"},{"issue":"1","key":"10.1016\/j.bone.2026.117873_bb0160","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00002826-198702000-00009","article-title":"Long-term influence of levodopa on bone mass and growth hormone in postmenopausal women with Parkinson\u2019s disease","volume":"10","author":"Rico","year":"1987","journal-title":"Clin. Neuropharmacol."},{"issue":"2","key":"10.1016\/j.bone.2026.117873_bb0165","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s00223-009-9327-6","article-title":"Hyperhomocysteinemia due to levodopa treatment as a risk factor for osteoporosis in patients with Parkinson\u2019s disease","volume":"86","author":"Lee","year":"2010","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2026.117873_bb0170","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3389\/fnagi.2015.00203","article-title":"Lower bone mineral density in patients with Parkinson\u2019s disease: a cross-sectional study from Chinese mainland","volume":"7","author":"Gao","year":"2015","journal-title":"Front. Aging Neurosci."},{"issue":"4","key":"10.1016\/j.bone.2026.117873_bb0175","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/mds.870080416","article-title":"Relationship between osteopenia and clinical characteristics of Parkinson\u2019s disease","volume":"8","author":"Ishizaki","year":"1993","journal-title":"Mov. Disord."},{"issue":"7","key":"10.1016\/j.bone.2026.117873_bb0180","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1007\/s10072-020-04920-6","article-title":"Association between freezing of gait and bone mineral density in patients with Parkinson\u2019s disease","volume":"42","author":"Choi","year":"2021","journal-title":"Neurol. Sci."},{"issue":"3","key":"10.1016\/j.bone.2026.117873_bb0185","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/mds.22866","article-title":"Homocysteine-lowering therapy or antioxidant therapy for bone loss in Parkinson\u2019s disease","volume":"25","author":"Lee","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bone.2026.117873_bb0190","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.1053786","article-title":"Low skull bone density is associated with poor motor prognosis in women with Parkinson\u2019s disease","volume":"14","author":"Jeong","year":"2022","journal-title":"Front. Aging Neurosci."},{"issue":"3","key":"10.1016\/j.bone.2026.117873_bb0195","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00223-007-9065-6","article-title":"Fracture risk associated with parkinsonism and anti-Parkinson drugs","volume":"81","author":"Vestergaard","year":"2007","journal-title":"Calcif. Tissue Int."},{"issue":"20","key":"10.1016\/j.bone.2026.117873_bb0200","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1056\/NEJMoa032546","article-title":"Homocysteine levels and the risk of osteoporotic fracture","volume":"350","author":"Meurs","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.bone.2026.117873_bb0205","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/mdc3.12386","article-title":"Postural, bone, and joint disorders in Parkinson\u2019s disease","volume":"3","author":"Rabin","year":"2016","journal-title":"Mov Disord Clin Pract"},{"issue":"3","key":"10.1016\/j.bone.2026.117873_bb0210","article-title":"Frail older adults with high anticholinergic burden are at risk of orthostatic hypotension","volume":"26","author":"Naharci","year":"2025","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"10.1016\/j.bone.2026.117873_bb0215","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.3389\/fnins.2019.01309","article-title":"Anticholinergic drugs in geriatric psychopharmacology","volume":"13","author":"Lopez-Alvarez","year":"2019","journal-title":"Front. Neurosci."},{"issue":"4","key":"10.1016\/j.bone.2026.117873_bb0220","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1474-4422(21)00377-X","article-title":"Cholinergic system changes in Parkinson\u2019s disease: emerging therapeutic approaches","volume":"21","author":"Bohnen","year":"2022","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.bone.2026.117873_bb0225","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40780-021-00213-y","article-title":"A meta-analysis of observational studies on anticholinergic burden and fracture risk: evaluation of conventional burden scales","volume":"7","author":"Ogawa","year":"2021","journal-title":"J Pharm Health Care Sci"},{"issue":"1","key":"10.1016\/j.bone.2026.117873_bb0230","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/mds.20261","article-title":"Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson\u2019s disease patients","volume":"20","author":"Lamberti","year":"2005","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.bone.2026.117873_bb0235","doi-asserted-by":"crossref","DOI":"10.1093\/ageing\/afaf052","article-title":"Assessing and managing bone health and fracture risk in Parkinson\u2019s disease: the BONE PARK 2 protocol","volume":"54","author":"Naylor","year":"2025","journal-title":"Age Ageing"},{"issue":"10","key":"10.1016\/j.bone.2026.117873_bb0240","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s00702-015-1396-2","article-title":"Falls in ambulatory non-demented patients with Parkinson\u2019s disease","volume":"122","author":"Rascol","year":"2015","journal-title":"J. Neural Transm. (Vienna)"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328226000992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328226000992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T20:30:03Z","timestamp":1784233803000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328226000992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":48,"alternative-id":["S8756328226000992"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2026.117873","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effects of anti-Parkinsonian medications on bone mineral density: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2026.117873","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117873"}}